Bicyclol Inhibitor

POWDER

99.8%

For 3 years at -20 degree C (powder)
For 2 years -80 degree C in solvent.

390.34

118159-48-1

C19H18O9

Microbiology & Virology

COC(=O)c1cc(OC)c2OCOc2c1-c1c2OCOc2c(OC)cc1CO

HBV

Bicyclol (SY 801) is a anti-hepatitis drug. Target: HBV Oral administration of bicyclol normalized the elevated serum transaminases (ALT, AST) by approximately 50% in chronic viral hepatitis B and C, and also showed certain level of inhibiting HBV and HCV replication. No noticeable adverse reaction has been observed. In combination therapy of bicyclol with interferon alpha, lamivudine and adefovir dipivoxil in HBV or HCV, bicyclol may potentiate the anti-viral efficacy and reduce YMDD mutant and side effects. In 2004 China FDA issued license to manufacture bicyclol. Since then bicyclol has been widely used to treat chronic HBV and HCV in China.

For obtaining a higher solubility, please warm the tube at 37 degree C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20 degree C for several month.

Metbolism; Cancer